問卷

TPIDB > Search Result

Search Result

篩選

List

4Cases

2020-08-01 - 2024-07-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-11-01 - 2031-03-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-09-29 - 2025-01-16

Phase III

A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
  • Condition/Disease

    Contrast-enhanced MRI is used to assess known or suspected pathology in body sites.

  • Test Drug

    Gadoquatrane (BAY 1747846) Dotarem (Gadoteric acid)

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated1Sites